|
| 胶原肽联合钙尔奇D治疗绝经后骨质疏松患者疗效分析 |
| Effects of collagen peptide combined with Caltrate D on the treatment of postmenopausal osteoporosis |
| |
| DOI：10.3969/j.issn.1006-7108.2019.02.018 |
| 中文关键词: 胶原肽 钙尔奇D 绝经后骨质疏松 骨密度 |
| 英文关键词:collagen peptide Caltrate D postmenopausal osteoporosis bone mineral density |
| 基金项目:内蒙古自治区科技计划项目(00116240) |
|
| 摘要点击次数: 3084 |
| 全文下载次数: 1697 |
| 中文摘要: |
| 目的 研究胶原肽联合钙尔奇D对绝经后骨质疏松患者的疗效分析。方法 202例绝经后骨质疏松症患者随机分为试验组(每天口服胶原肽10 g联合钙尔奇D 600 mg)和对照组（口服钙尔奇D 600 mg），进行为期6个月的治疗。利用化学发光法检测血清总骨1型前胶原N端肽(N-propeptide of type 1 collagen，PINP）、β-I型胶原交联羧基末端肽（C-terminal crosslinked telopeptides of type 1 collagen，β-CTX）、血清骨钙素（osteocalcin，OC）、25-羟维生素D3[25 hydroxy vitamine D3，25(OH)D3]、甲状旁腺素(parathyroid hormone，PTH)。利用双能X线(dual energy X-ray absorptiometry，DXA)吸收法进行腰椎、股骨骨密度(bone mineral density，BMD)检测。结果 治疗6个月后，口服胶原肽联合钙尔奇D能够更有效地缓解骨质疏松导致的骨痛。试验组患者血清PTH、25(OH)D3及OC水平明显高于治疗前(P＜0.01)及对照组（P＜0.01）。对照组患者治疗后血清PINP水平明显低于治疗前(P＜0.01），而PTH、25(OH)D3、β-CTX水平明显高于治疗前(P＜0.01)。试验组患者治疗后血清PINP水平明显高于对照组（P＜0.01），而β-CTX水平低于对照组（P＜0.05）。试验组患者腰椎L2、L4及股骨颈、粗隆间BMD明显高于治疗前(P＜0.01）及对照组(P＜0.05）。试验组患者各部位BMD均显著高于治疗前(P＜0.01）；而对照组患者治疗后上述各指标差异无统计学意义(P＞0.05)。结论 口服胶原肽联合钙尔奇D既能促进骨形成，又能抑制骨吸收，进一步增加BMD，并且可以缓解骨质疏松引起的疼痛。 |
| 英文摘要: |
| Objective To study the effects of bone collagen peptide combined with Caltrate D on the treatment of postmenopausal osteoporosis. Methods 202 postmenopausal women with osteoporosis were randomized to receive oral administration of 10 g collagen peptide combined with 600mg Caltrate D (experimental group) or 600mg Caltrate D (control group) daily for 6 months. Serum total N-terminal propeptide of type I procollagen (PINP), β-isomerized C-terminal cross-linked telopeptide of type I collagen (β-CTX), N-MID Osteocalcin (OC), 25-hydroxyvitamin D3 (25-OH D3) and parathyroid hormone (PTH) were detected by chemiluminescence. BMD of the lumbar spine and the femur was measured using dual-energy X-ray absorption. Results After 6 months of treatment, oral collagen peptide combined with Caltrate D was more effective in alleviating bone pain caused by osteoporosis. The levels of serum PTH, 25-OH D3 and N-MID Osteocalcin (OC) in the experimental group were significantly higher than those before treatment (P<0.01) and the control group (P<0.01). Serum PINP level of the control group after treatment was significantly lower than that before treatment (P<0.01), while the levels of PTH, 25-OH D3 and beta -CTX were significantly higher than those before treatment (P<0.01). Serum PINP level in the experimental group was significantly higher than that in the control group (P<0.01), while the level of ? -CTX in the experimental group was lower than that in the control group (P<0.05). BMD of L2-L4 of lumbar spine and of femoral neck and intertrochanter of femur in the experimental group was significantly higher than that before treatment (P<0.01) and the control group (P<0.05). BMD of all sites in the experimental group was significantly higher than that before treatment (P<0.01), but there was no statistical significance in the above indexes after treatment in the control group (P>0.05). Conclusion Oral collagen peptide combined with Caltrate D not only could promote bone formation, but also could inhibit bone absorption, further increase BMD and alleviate the pain caused by osteoporosis. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |